CH626808A5 - - Google Patents
Download PDFInfo
- Publication number
- CH626808A5 CH626808A5 CH1683374A CH1683374A CH626808A5 CH 626808 A5 CH626808 A5 CH 626808A5 CH 1683374 A CH1683374 A CH 1683374A CH 1683374 A CH1683374 A CH 1683374A CH 626808 A5 CH626808 A5 CH 626808A5
- Authority
- CH
- Switzerland
- Prior art keywords
- plasminogen
- solution
- inhibitor
- placental
- pulps
- Prior art date
Links
- 102000013566 Plasminogen Human genes 0.000 claims description 107
- 108010051456 Plasminogen Proteins 0.000 claims description 107
- 230000003169 placental effect Effects 0.000 claims description 41
- 239000000243 solution Substances 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 31
- 239000003112 inhibitor Substances 0.000 claims description 26
- 235000018102 proteins Nutrition 0.000 claims description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 102000004169 proteins and genes Human genes 0.000 claims description 21
- 150000001875 compounds Chemical class 0.000 claims description 18
- 210000004369 blood Anatomy 0.000 claims description 14
- 239000008280 blood Substances 0.000 claims description 14
- 210000002826 placenta Anatomy 0.000 claims description 13
- 238000000926 separation method Methods 0.000 claims description 12
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 11
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 11
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 11
- 238000002803 maceration Methods 0.000 claims description 11
- 238000001556 precipitation Methods 0.000 claims description 11
- 238000000502 dialysis Methods 0.000 claims description 10
- 239000002244 precipitate Substances 0.000 claims description 10
- 230000007935 neutral effect Effects 0.000 claims description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 238000000746 purification Methods 0.000 claims description 8
- 235000001014 amino acid Nutrition 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-Lysine Natural products NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 6
- 238000001042 affinity chromatography Methods 0.000 claims description 6
- 239000012535 impurity Substances 0.000 claims description 6
- 239000004472 Lysine Substances 0.000 claims description 5
- 229960002684 aminocaproic acid Drugs 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 238000010257 thawing Methods 0.000 claims description 4
- GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical group NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 230000033885 plasminogen activation Effects 0.000 claims description 3
- 235000019766 L-Lysine Nutrition 0.000 claims description 2
- 230000008030 elimination Effects 0.000 claims description 2
- 238000003379 elimination reaction Methods 0.000 claims description 2
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 claims 1
- 230000002779 inactivation Effects 0.000 claims 1
- 239000011344 liquid material Substances 0.000 claims 1
- 238000004537 pulping Methods 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000011343 solid material Substances 0.000 claims 1
- 239000012265 solid product Substances 0.000 claims 1
- 239000007858 starting material Substances 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 238000000605 extraction Methods 0.000 description 18
- 108010088842 Fibrinolysin Proteins 0.000 description 16
- 229940012957 plasmin Drugs 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 230000004913 activation Effects 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- 239000000872 buffer Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 210000002381 plasma Anatomy 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 239000001166 ammonium sulphate Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000003527 fibrinolytic agent Substances 0.000 description 3
- 235000018977 lysine Nutrition 0.000 description 3
- 230000000896 plasminic effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- UAFHRUBCOQPFFM-UHFFFAOYSA-N 1-(aminomethyl)cyclohexane-1-carboxylic acid Chemical compound NCC1(C(O)=O)CCCCC1 UAFHRUBCOQPFFM-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108010023197 Streptokinase Proteins 0.000 description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000022 bacteriostatic agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000963 caseinolytic effect Effects 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000010907 mechanical stirring Methods 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011403 purification operation Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229960005202 streptokinase Drugs 0.000 description 2
- 229960005356 urokinase Drugs 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000766026 Coregonus nasus Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical group CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 101000605403 Homo sapiens Plasminogen Proteins 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 206010073734 Microembolism Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000012443 analytical study Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940001501 fibrinolysin Drugs 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 230000002879 macerating effect Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 108010057207 plasminogen-valine Proteins 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7345289A FR2254316B1 (nl) | 1973-12-18 | 1973-12-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH626808A5 true CH626808A5 (nl) | 1981-12-15 |
Family
ID=9129388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH1683374A CH626808A5 (nl) | 1973-12-18 | 1974-12-18 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US4115551A (nl) |
| JP (1) | JPS6042207B2 (nl) |
| AU (1) | AU508321B2 (nl) |
| BE (1) | BE823522A (nl) |
| CA (1) | CA1046406A (nl) |
| CH (1) | CH626808A5 (nl) |
| DE (1) | DE2459915C3 (nl) |
| DK (1) | DK144023C (nl) |
| ES (1) | ES433002A1 (nl) |
| FR (1) | FR2254316B1 (nl) |
| GB (1) | GB1495289A (nl) |
| IE (1) | IE40555B1 (nl) |
| NL (1) | NL183462C (nl) |
| SE (1) | SE431613B (nl) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2347048A2 (fr) * | 1976-04-07 | 1977-11-04 | Choay Sa | Compositions constituees par des composes du type plasminogene, notamment d'origine placentaire, procede d'obtention des ces compositions, et medicaments contenant ces compositions |
| CH635748A5 (fr) * | 1977-08-16 | 1983-04-29 | Cellorgan Laboratoires Sa | Procede d'obtention de cellules placentaires de brebis. |
| JPH0310563Y2 (nl) * | 1986-06-25 | 1991-03-15 | ||
| US5204447A (en) * | 1988-11-14 | 1993-04-20 | Zymogenetics, Inc. | Purification of factor xiii |
| AU1191001A (en) * | 1999-10-07 | 2001-05-10 | Human Genome Sciences, Inc. | Plasminogen-like polynucleotides, polypeptides, and antibodies |
| US6969515B2 (en) * | 1999-11-13 | 2005-11-29 | Talecris Biotherapeutics, Inc. | Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin |
| US6355243B1 (en) | 1999-11-13 | 2002-03-12 | Bayer Corporation | Method of thrombolysis by local delivery of active plasmin |
| US7544500B2 (en) * | 1999-11-13 | 2009-06-09 | Talecris Biotherapeutics, Inc. | Process for the production of a reversibly inactive acidified plasmin composition |
| US6964764B2 (en) * | 1999-11-13 | 2005-11-15 | Talecris Biotherapeutics, Inc. | Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin |
| US20030134794A1 (en) * | 2001-11-20 | 2003-07-17 | Madison Edwin L. | Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon |
| US8617863B2 (en) * | 2008-06-04 | 2013-12-31 | Grifols Therapeutics Inc. | Composition, method, and kit for preparing plasmin |
| JP5789521B2 (ja) | 2009-03-03 | 2015-10-07 | グリフオルス・セラピユーテイクス・インコーポレーテツドＧｒｉｆｏｌｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | プラスミノーゲンを製造するための組成物、方法およびキット；ならびにそれから製造されるプラスミン |
| TWI801331B (zh) * | 2015-11-03 | 2023-05-11 | 美商波麥堤克生物治療股份有限公司 | 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法 |
| CN113597313A (zh) * | 2019-01-24 | 2021-11-02 | 先觉药业咨询公司 | 用于治疗和预防微血栓形成的纤溶酶原 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL120993C (nl) * | 1962-08-31 | |||
| US3234106A (en) * | 1962-12-03 | 1966-02-08 | Cutter Lab | Soluble, purified profibrinolysin and fibrinolysin and method of producing same |
| AT259135B (de) * | 1964-03-20 | 1967-12-27 | Novo Terapeutisk Labor As | Verfahren zur Gewinnung von Plasminogen aus Blutserum oder Blutplasma |
| DE2057041C3 (de) * | 1970-11-20 | 1973-12-20 | Duerkoppwerke Gmbh, 4800 Bielefeld | Vorrichtung zum Stapeln flexibler Arbeitsstücke |
-
1973
- 1973-12-18 FR FR7345289A patent/FR2254316B1/fr not_active Expired
-
1974
- 1974-12-13 CA CA215,976A patent/CA1046406A/en not_active Expired
- 1974-12-14 AU AU76534/74A patent/AU508321B2/en not_active Expired
- 1974-12-17 ES ES433002A patent/ES433002A1/es not_active Expired
- 1974-12-17 US US05/533,631 patent/US4115551A/en not_active Expired - Lifetime
- 1974-12-17 DK DK657074A patent/DK144023C/da not_active IP Right Cessation
- 1974-12-17 GB GB54444/74A patent/GB1495289A/en not_active Expired
- 1974-12-17 IE IE2600/74A patent/IE40555B1/xx unknown
- 1974-12-18 DE DE2459915A patent/DE2459915C3/de not_active Expired
- 1974-12-18 NL NLAANVRAGE7416522,A patent/NL183462C/nl not_active IP Right Cessation
- 1974-12-18 JP JP49145532A patent/JPS6042207B2/ja not_active Expired
- 1974-12-18 CH CH1683374A patent/CH626808A5/fr not_active IP Right Cessation
- 1974-12-18 BE BE151650A patent/BE823522A/xx not_active IP Right Cessation
- 1974-12-18 SE SE7415963A patent/SE431613B/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| SE431613B (sv) | 1984-02-20 |
| BE823522A (fr) | 1975-06-18 |
| NL7416522A (nl) | 1975-06-20 |
| ES433002A1 (es) | 1976-09-01 |
| IE40555L (en) | 1975-06-18 |
| NL183462B (nl) | 1988-06-01 |
| IE40555B1 (en) | 1979-07-04 |
| US4115551A (en) | 1978-09-19 |
| NL183462C (nl) | 1988-11-01 |
| SE7415963L (nl) | 1975-06-19 |
| DE2459915C3 (de) | 1986-06-19 |
| DE2459915B2 (de) | 1980-06-19 |
| FR2254316B1 (nl) | 1977-04-22 |
| AU7653474A (en) | 1976-06-17 |
| JPS50116611A (nl) | 1975-09-12 |
| JPS6042207B2 (ja) | 1985-09-20 |
| DE2459915A1 (de) | 1975-06-26 |
| GB1495289A (en) | 1977-12-14 |
| FR2254316A1 (nl) | 1975-07-11 |
| DK144023C (da) | 1982-05-03 |
| DK657074A (nl) | 1975-08-25 |
| AU508321B2 (en) | 1980-03-20 |
| DK144023B (da) | 1981-11-23 |
| CA1046406A (en) | 1979-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH626808A5 (nl) | ||
| EP0503991B1 (fr) | Procédé de préparation à l'échelle industrielle d'un concentré de facteur von Willebrand humain standardisé, de très haute pureté, approprié à un usage thérapeutique | |
| EP0033686B1 (fr) | Procédé de traitement d'une matière première à base de caséine, contenant des phosphocaséinates de cations bivalents, produits obtenus et applications | |
| FR2593393A1 (fr) | Solution aqueuse a usage parenteral d'activateur tissulaire du plasminogene, procede pour la preparer et recipient obture la contenant | |
| FR2583984A1 (fr) | Formulation pharmaceutique lyophilisee d'activateur tissulaire du plasminogene, procede pour la preparer, recipient obture la contenant et sel d'activateur tissulaire du plasminogene | |
| FR2576752A1 (fr) | Procede de purification de proteines du lait et de ses derives | |
| JPH10501522A (ja) | 因子ｖｉｉｉまたは因子ｉｘの皮下、筋肉内または皮内投与用の製薬調合剤 | |
| FR2501692A1 (fr) | Nouveau produit d'erythropoietine et procede pour sa preparation | |
| FR2600895A1 (fr) | Utilisation de l'activateur tissulaire du plasminogene, son association avec une superoxyde-dismutase et formulation pharmaceutique contenant cette association | |
| CH668428A5 (fr) | Procede d'extraction de proteines du lait, produits, application du procede et compositions pharmaceutiques. | |
| FR2540121A1 (fr) | Procede de preparation d'un facteur stimulant des colonies et de kallikreine provenant de l'urine humaine | |
| FR2497229A1 (fr) | Procede de preparation d'un derive polysaccharidique de fibrinolysine | |
| EP0512883B1 (fr) | Procédé de préparation d'un concentré de facteur XI de la coagulation sanguine à haute activité spécifique, approprié à un usage thérapeutique | |
| EP0274939A2 (fr) | Procédé de préparation d'un mélange peptidique riche en di- et tripeptides utilisable notamment en nutrition artificielle et en diététique, mélange ainsi obtenu, et utilisation de ce mélange en nutrition artificielle et en diététique | |
| CA3029075A1 (fr) | Fibrinogene liquide stable | |
| EP0397571A1 (fr) | Utilisation du caséinoglycopeptide k pour la fabrication d'une composition, notamment d'un médicament, pour la prévention et le traitement des thromboses | |
| EP1297116A2 (fr) | Procede d'isolement et de purification d'une proteine, et proteine obtenue | |
| FR2672895A1 (fr) | Procede de purification d'une proteine fortement glycosylee. | |
| JPS62255430A (ja) | 哺乳動物の脈管病を治療する方法 | |
| EP0383645B1 (fr) | Procédé de fabrication du facteur antihémophilique (FVIIIc) ayant une très haute pureté. | |
| CZ191098A3 (cs) | Způsob výroby hyaluronidázy a její použití | |
| FR2495634A1 (fr) | Enzyme nouvelle et utilisable en therapeutique | |
| WO1992000014A1 (fr) | Procede de traitement du colostrum par chromatographie d'adsorption sur hydroxyapatite, fraction active de colostrum obtenue et milieu cellulaire contenant ladite fraction active | |
| EP0219400B1 (fr) | Glycopeptides et glycoprotéines, toute composition les contenant leur procédé de préparation et leurs applications anticoagulantes | |
| EP0317439A1 (fr) | Sérum de nature humaine obtenu à partir de fractions résultant du fractionnement de sang ou de plasma humain, son procédé de préparation et réactif de laboratoire contenant ledit sérum |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |